Journal
MOLECULAR IMAGING AND BIOLOGY
Volume 10, Issue 5, Pages 271-280Publisher
SPRINGER
DOI: 10.1007/s11307-008-0151-6
Keywords
3 '-[F-18]fluoro-3 '-deoxythymidine; FLT; fluorothymidine; positron emission tomography (PET); glioma; glioblastoma; safety; toxicity; proliferation
Funding
- NCI NIH HHS [N01-CM-37008, P01 CA042045, N01CM37008] Funding Source: Medline
- NCRR NIH HHS [S10 RR17229] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [P01CA042045] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR017229] Funding Source: NIH RePORTER
Ask authors/readers for more resources
3'-[F-18]Fluoro-3'-deoxythymidine (FLT) is an analog of thymidine that is being developed for imaging cellular proliferation. The goal of this study was to prove that the dose of FLT used for positron emission tomography imaging produces no significant toxicity. Twelve patients with gliomas with either recurrence or suspected radionecrosis were imaged with FLT. Before and at several time points after imaging, subjects underwent general physical and neurological examinations with review of systems and tests of hematologic, hepatic, renal, and several other metabolic parameters. Vital signs and electrocardiograms were monitored during and after the imaging session. There were no significant adverse effects from FLT injected at a dose of 0.07 mCi/kg (maximum of 5 mCi) at specific activities of 1.25 Ci/mu mol or higher. The FLT mass administered for imaging was 0.0001% to 0.0009% of the least toxic cumulative dose administered in clinical trials of FLT as an antiretroviral agent. FLT is a safe radiotracer for quantifying proliferation in the human cancer setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available